Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Unsaturated fatty acids, particularly monounsaturated (MUFA) and polyunsaturated fatty acids (PUFA, which include omega-3 and omega-6), have a substantial body of scientific evidence supporting their use in managing Metabolic Syndrome (MetS). Metabolic Syndrome is characterized by a cluster of conditions including insulin resistance, central obesity, dyslipidemia, and hypertension. Numerous epidemiological studies and randomized controlled trials have shown that replacing saturated fats with unsaturated fats in the diet improves several MetS components. For example, omega-3 PUFA from fish oil are known to lower triglyceride levels, reduce inflammation, and may improve endothelial function. Likewise, MUFA, found in olive oil and nuts, have been associated with improved insulin sensitivity and lipid profiles. The Mediterranean diet, which is rich in unsaturated fatty acids, is correlated with a lower incidence of MetS and its related complications. Mechanistically, unsaturated fatty acids modulate lipid metabolism, exert anti-inflammatory effects, and influence gene expression involved in glucose and lipid homeostasis. Systematic reviews and meta-analyses of intervention studies generally support moderate to strong benefits of unsaturated fat intake for improving markers relevant to MetS, although some heterogeneity exists in outcomes depending on the type and source of fats. Overall, the use of unsaturated fatty acids to support or treat Metabolic Syndrome is well-grounded in current scientific literature.

More about Unsaturated fatty acid
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Unsaturated fatty acid

Products containing Unsaturated fatty acid